Utah Cannabinoid Product Board
Position Statement: delta-8 THC and related synthetic/derived cannabinoids

The Utah Cannabinoid Product Board (CPB) is charged with reviewing available research literature and assisting the Utah Department of Health (UDOH) and Center for Medical Cannabis in their efforts to provide useful treatment recommendations to qualified medical providers regarding the use of cannabis and cannabinoid products for treatment of certain medical conditions identified as ‘qualifying medical conditions’.

Delta-8 THC is a psychoactive cannabinoid found in trace amounts in cannabis plants, and readily synthesized from cannabidiol (CBD). Because concentrated, synthesized or otherwise derived formulations of delta-8 THC are available to consumers in Utah, in accordance with its charge, the CPB has reviewed available literature pertaining to delta-8 THC, and the topic was discussed in an open public meeting of the CPB.

At this time there is no evidence of therapeutic benefit of the analog/derived/synthesized cannabinoids (including delta-8 THC). Risks have been described by federal regulatory bodies and peer review publications regarding delta-8 THC. At this time we do not support any therapeutic uses of analog cannabis products.